GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $73 billion and impressive gross margins of 72%, announced today that the China National Medical (TASE ...

GSK (GSK) announced that the China National Medical Products Administration, CNMPA, has accepted for review the new drug application for the ...

China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China. The London-based pharmaceutical company said the China Medical Products ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

This can be found among the Granolas, a group of 11 European multinationals, selected by US bank Goldman Sachs, which is made ...

These latest developments come just a few weeks after DeepSeek's release of a lower-cost AI model rattled markets, as it ...

A roundup of recent health news highlights policy changes affecting FDA language use, drug industry meetings with President ...

GSK is enlisting the aid of China’s Chongqing Zhifei Biological Products (Zhifei) to drive sales of its most important vaccine, Shingrix, in China over the next few years, and may also call upon ...